DEXCOM, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 137.9 USD | +2.89% |
|
+3.00% | +11.10% |
| Apr. 22 | John Chevedden Submits a Shareholder Proposal to DexCom | CI |
| Apr. 22 | Myra K. Young Submits a Shareholder Proposal to DexCom | CI |
Presentation Operator MessageOperator (Operator)Welcome to the DexCom Fourth Quarter 2021 Earn...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals.
The United States accounts for 72.5% of net sales.
Calendar
2024-04-24
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
137.9
USD
Average target price
149.3
USD
Spread / Average Target
+8.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.10% | 54.6B | |
| -2.89% | 185B | |
| -2.43% | 107B | |
| -4.10% | 67.55B | |
| +15.86% | 47.42B | |
| +3.66% | 42.24B | |
| +9.55% | 28.24B | |
| +1.85% | 26.42B | |
| +12.89% | 25.66B | |
| -0.44% | 24.9B |
- Stock Market
- Equities
- DXCM Stock
- News DexCom, Inc.
- Transcript : DexCom, Inc., Q4 2021 Earnings Call, Feb 10, 2022
